In head-to-head comparisons with other cytokine inhibitors (e.g., anti-TNF therapies), anakinra has shown relatively modest efficacy in RA, highlighting an unmet need for more potent and/or longer-acting IL-1-targeting agents 8, 9. This evidence concerns the gene IL1A and rheumatoid arthritis.